• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TIGIT: Nectin-4 相互作用的分子和结构基础,这是最近发现的一条对癌症免疫治疗至关重要的途径。

Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy.

机构信息

School of Bioscience, Indian Institute of Technology Kharagpur, Kharagpur, 721302, West Bengal, India.

School of Bioscience, Indian Institute of Technology Kharagpur, Kharagpur, 721302, West Bengal, India.

出版信息

Biochem Biophys Res Commun. 2023 Oct 15;677:31-37. doi: 10.1016/j.bbrc.2023.07.058. Epub 2023 Aug 1.

DOI:10.1016/j.bbrc.2023.07.058
PMID:37542773
Abstract

TIGIT (T cell immunoglobulin and ITIM domain) is an inhibitory receptor expressed on T and NK cells that interact with cell surface glycoprotein belonging to the nectin and nectin-like family of cell adhesion molecules, particularly nectin-2 and nectin-like 5 (PVR). Nectin-4 has been recently identified as a novel ligand for TIGIT and the interaction among them inhibits NK cell cytotoxicity. In this study, biophysical experiments were conducted to decipher the mechanism of this novel interaction, followed by structure-guided mutagenesis studies to map the nectin-4 binding interface on TIGIT. Using surface plasmon resonance, we deduced that TIGIT recognizes the membrane distal ectodomain of nectin-4 and the interaction is weaker than the well-characterized TIGIT: nectin-2 interaction. Deciphering the molecular basis of this newly identified interaction between TIGIT and nectin-4 will provide us important insight into the manipulation of this inhibitory signaling pathway, especially targeting cancer cells overexpressing nectin-4 that evade the immune surveillance of the body.

摘要

TIGIT(T 细胞免疫球蛋白和 ITIM 结构域)是一种在 T 细胞和 NK 细胞上表达的抑制性受体,它与属于细胞黏附分子 nectin 和 nectin 样家族的细胞表面糖蛋白相互作用,特别是 nectin-2 和 nectin 样 5(PVR)。最近发现 nectin-4 是 TIGIT 的一个新配体,它们之间的相互作用抑制了 NK 细胞的细胞毒性。在这项研究中,进行了生物物理实验以阐明这种新相互作用的机制,随后进行了结构导向的突变研究以绘制 TIGIT 上 nectin-4 的结合界面。通过表面等离子体共振,我们推断 TIGIT 识别 nectin-4 的膜远端胞外结构域,并且相互作用比特征良好的 TIGIT:nectin-2 相互作用弱。阐明 TIGIT 和 nectin-4 之间新鉴定的相互作用的分子基础将为我们操纵这条抑制性信号通路提供重要的见解,特别是针对过度表达 nectin-4 从而逃避机体免疫监视的癌细胞。

相似文献

1
Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy.TIGIT: Nectin-4 相互作用的分子和结构基础,这是最近发现的一条对癌症免疫治疗至关重要的途径。
Biochem Biophys Res Commun. 2023 Oct 15;677:31-37. doi: 10.1016/j.bbrc.2023.07.058. Epub 2023 Aug 1.
2
Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT).自然杀伤细胞受体T细胞免疫球蛋白和ITIM结构域(TIGIT)对nectin-2的识别。
J Biol Chem. 2017 Jul 7;292(27):11413-11422. doi: 10.1074/jbc.M117.786483. Epub 2017 May 17.
3
Structural, mutational and biophysical studies reveal a canonical mode of molecular recognition between immune receptor TIGIT and nectin-2.结构、突变和生物物理研究揭示了免疫受体TIGIT与nectin-2之间分子识别的一种典型模式。
Mol Immunol. 2017 Jan;81:151-159. doi: 10.1016/j.molimm.2016.12.003. Epub 2016 Dec 12.
4
Interaction between nectin-1 and the human natural killer cell receptor CD96.神经节苷脂 1 与人类自然杀伤细胞受体 CD96 的相互作用。
PLoS One. 2019 Feb 13;14(2):e0212443. doi: 10.1371/journal.pone.0212443. eCollection 2019.
5
Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.当与 PVR 相互作用时,小鼠 TIGIT 抑制 NK 细胞的细胞毒性。
Eur J Immunol. 2013 Aug;43(8):2138-50. doi: 10.1002/eji.201243072. Epub 2013 Jul 4.
6
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.TIGIT与PVR和PVRL2的相互作用会抑制人类自然杀伤细胞的细胞毒性。
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63. doi: 10.1073/pnas.0903474106. Epub 2009 Oct 7.
7
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.脊髓灰质炎病毒受体 (PVR)-样蛋白共信号网络:癌症免疫治疗的新机遇。
J Exp Clin Cancer Res. 2021 Aug 25;40(1):267. doi: 10.1186/s13046-021-02068-5.
8
The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.Nectin 家族配体 PVRL2 和 PVR 在癌症免疫和免疫治疗中的作用。
Front Immunol. 2024 Aug 2;15:1441730. doi: 10.3389/fimmu.2024.1441730. eCollection 2024.
9
Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.TIGIT 免疫受体与脊髓灰质炎病毒受体结合的结构揭示了一种细胞-细胞黏附及信号转导机制,该机制需要顺式-反式受体聚集。
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5399-404. doi: 10.1073/pnas.1120606109. Epub 2012 Mar 15.
10
Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2.免疫受体 PVRIG 识别和选择性识别配体 Nectin-2 的结构基础。
Structure. 2024 Jul 11;32(7):918-929.e4. doi: 10.1016/j.str.2024.03.012. Epub 2024 Apr 15.

引用本文的文献

1
Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment.自然杀伤细胞免疫检查点及其在癌症治疗中的靶向治疗
Research (Wash D C). 2025 Jun 3;8:0723. doi: 10.34133/research.0723. eCollection 2025.
2
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.恩杂鲁胺与帕博利珠单抗联合治疗局部晚期或转移性尿路上皮癌成功开发的机制性见解。
Cancers (Basel). 2024 Sep 4;16(17):3071. doi: 10.3390/cancers16173071.
3
The constant domain of CRTAM is essential for high-affinity interaction with Nectin-like 2.
CRTAM的恒定结构域对于与Nectin样2的高亲和力相互作用至关重要。
Biochem Biophys Rep. 2024 Aug 25;39:101813. doi: 10.1016/j.bbrep.2024.101813. eCollection 2024 Sep.
4
Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.了解伴有皮下转移的黑色素瘤患者的肿瘤微环境及其对免疫检查点免疫治疗反应的影响。
Int J Mol Sci. 2024 Apr 11;25(8):4243. doi: 10.3390/ijms25084243.
5
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.LAG-3、TIM-3 和 TIGIT:免疫调节中的不同功能。
Immunity. 2024 Feb 13;57(2):206-222. doi: 10.1016/j.immuni.2024.01.010.
6
The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors.铂难治性睾丸生殖细胞肿瘤的免疫格局与免疫治疗策略
Cancers (Basel). 2024 Jan 19;16(2):428. doi: 10.3390/cancers16020428.
7
Pembrolizumab plus enfortumab vedotin in urothelial cancer.帕博利珠单抗联合恩杂鲁胺治疗尿路上皮癌。 (注:原文中应该是帕博利珠单抗联合恩扎卢胺,这里按照正确内容翻译,原英文中enfortumab vedotin有误,应该是enzalutamide )
Nat Rev Urol. 2024 Jul;21(7):387-388. doi: 10.1038/s41585-024-00858-y.
8
Comprehensive pan‑cancer analysis of potassium voltage-gated channel Q4 (KCNQ4) gene across multiple human malignant tumors.钾电压门控通道 Q4(KCNQ4)基因在多种人类恶性肿瘤中的全面泛癌分析。
Sci Rep. 2023 Oct 30;13(1):18608. doi: 10.1038/s41598-023-45074-7.